Researchers are studying various medications as potential treatments for individuals with RMC. Such treatments include bortezomib and ixazomib, which are drugs that block the removal of unwanted proteins from the cancer cells (proteasome inhibitors), as well as drugs that target certain pathways, such as the EZH2 pathway, that may be important for RMC. In addition, drugs that harness the body's immune system to recognize and kill RMC cells are also being investigated. Clinical trials are needed to determine the effectiveness and safety of these new therapies for patients with RMC. Clinical trials that enroll patients with RMC will normally also enroll patients with the RCCU-MP subtype. Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site. Ongoing clinical trials for patients with RMC and RCCU-MP: • Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer • Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma